Biomoda to Participate in Rodman & Renshaw Annual Healthcare Conference in New York City

08.30.2010 — 7:30 am

Albuquerque, NM – Cancer diagnostics company Biomoda, Inc. today announced that John Cousins, President and CEO, will present on Biomoda’s proprietary CyPath® diagnostic assay for the detection of early-stage cancers at the Rodman & Renshaw 12th Annual Healthcare Conference in New York on Wednesday, September 15, 2010.

The Healthcare Conference is one of eight industry tracks featured at the Rodman & Renshaw Annual Global Investment Conference.  Institutional investors, venture capitalists, private equity firms, business development executives and sophisticated private investors will have the opportunity to learn about Biomoda’s porphyrin-based CyPath® labeling solution that binds to cancer cells and causes them to fluoresce under specific frequencies of light.

Biomoda is concluding the pilot clinical trial on CyPath® as a diagnostic for early-stage lung cancer.  Pending Food and Drug Administration (FDA) approval, CyPath® is for investigational use only.

The Biomoda presentation is scheduled at 12:30 p.m. EDT on September 15 in the Spellman Salon, 5th Floor, New York Palace Hotel.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

About Rodman & Renshaw

Rodman & Renshaw is a full-service investment bank providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

Useful Links

Site Map Contact Us